Midnight Collapse: How Simufilam's Science Vanished and Patients Waited
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Midnight Collapse: How Simufilam's Science Vanished and Patients Waited
-
ナレーター：
-
著者：
There is a slow-motion intellectual horror in this story: a drug tested by hundreds of Alzheimer's patients rested almost entirely on data from one lab, and by November 25, 2024 the Phase III trials had failed and simufilam was declared dead - but the original data was never produced. How did a molecule called simufilam and a protein called filamin A come to carry sixteen million dollars of public research investment, only to evaporate alongside a criminal case dropped at midnight?
In this episode, we trace the arc from laboratory claims to clinical trials and a midnight legal collapse. We lay out how a single research program shaped a company's entire strategy, how co-authorship linked academia to industry, and why investigators kept finding the same missing piece: no underlying data. What does it mean for patients and science when the foundation cannot be verified?
Person: Hoau-Yan Wang
Person: Lindsay Burns
Company: Cassava Sciences
Event: Phase III trials failed and simufilam discontinued
Date: November 25, 2024
- Simufilam (PTI-125) was named by the United States Adopted Names council in August 2020.
- More than hundreds of patients enrolled in open-label studies beginning March 2020.
- The foundational mechanism was described in two papers published in 2012 (Journal of Neuroscience) and 2017 (Neurobiology of Aging).
- The NIH granted Cassava Sciences funding in 2018 to pursue early clinical trials.
- Sixteen million dollars in public research funds were connected to the work centered on filamin A.
To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.
© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません